Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinical trial will enroll approximately 80 patients at 10 centers in Europe, Australia and New Zealand, and will incorporate device enhancements designed to improve deliverability and vessel support. The first patient was enrolled into the second stage of the ABSORB clinical trial at Onze Lieve Vrouw Ziekenhuis Hospital in Aalst, Belgium, by Bernard De Bruyne, M.D., Ph.D.

"Interventional cardiology has come a long way. It started with balloon angioplasty, which evolved into bare metal stents and then drug eluting metal stents were created," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the ABSORB trial. "Now we have the fourth revolution in interventional cardiology technology, and patient outcomes from the first stage of ABSORB clearly show that bioabsorbable devices are the future of coronary artery disease treatment."

Results from the first stage of the ABSORB trial with 30 patients demonstrated that Abbott's bioabsorbable everolimus eluting stent successfully treated coronary artery disease, and that at two years, the treated vessel was able to expand and contract, without being restricted by a permanent implant - indicating that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major adverse cardiac events (MACE) between six months and two years, with the bioabsorbable device demonstrat
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
(Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
(Date:4/24/2014)... long thought to be boring and irrelevant, could offer ... disease. , Researcher Dr Milena Furtado, and her team ... University, found the heart cell fibroblast is a close ... healthy beating heart. , In research published today in ... cardiac fibroblasts are unique cells due to their genetic ...
(Date:4/24/2014)... CHAMPAIGN, Ill. It is better to give than to ... enjoy giving, a new study suggests. , The study found ... such as giving their money to family members, are less ... thrill from taking risks or keeping the money for themselves. ... of the National Academy of Sciences . , The study ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
(Date:4/23/2014)... stool from healthy, unrelated donors was safe and ... caused by Clostridium difficile , according to ... Infectious Diseases and available online. Known as ... whether given via a colonoscope or a nasogastric ... this promising treatment more readily available to patients. ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
... 2008) The American Heart Associations Los Angeles Division ... of the paramedic model in use around the country ... Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). ... Heart Awards to Dr. Criley and William Koenig, Los ...
... April 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ... services, today announced that it entered into a ... security agreement with Sovereign,Business Capital ("SBC", formerly Business ... the loan credit facility, SBC takes,assignment of TeamStaff,s ...
... WEST BEND, Wis., April 3, 2008 Mach ... that the,final tests prior to large scale manufacturing ... week., "A highly qualified scientist from BioQual ... facility completing a technology transfer and,memorializing the protocols ...
... Earns Vesicare Gold Standard Status Over, Sales-Leading Detrol LA/Detrusitol ... ... Decision Resources, WALTHAM, Mass., April 3, 2008 Decision Resources, ... healthcare issues, finds that a drug,s effect on the,reduction of urge ...
... gases, radiation and pesticides as probable causes , , THURSDAY, ... the risk of miscarriage, apparently the result of being ... line of work, a new study found. , Not ... the risks, but veterinary offices and labs need to ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... company that develops, manufactures and markets advanced,in-vitro ... tumor,therapy systems, today announced the completion of ... (the "Kit"), a prostate cancer-specific,molecular diagnostic test ...
Cached Medicine News:Health News:Pioneer of paramedic model to be honored 2Health News:Pioneer of paramedic model to be honored 3Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Mach One Corporation Announces Completion of Final Tests Prior to Full Scale Production 2Health News:Astellas/GlaxoSmithKline's Vesicare Has Advantages Over Pfizer's Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence 2Health News:Women Veterinarians Face Higher Miscarriage Risk 2Health News:Women Veterinarians Face Higher Miscarriage Risk 3Health News:China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent 2
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
... These revised charts incorporate the slight change ... the 10 Sloan letters derived from the ... eyes during the ETDRS study. The original ... examination of 234 eyes. In addition to ...
... to diagnose Stereo and Binocular vision in children ... glasses. The test can be used for testing ... and depth perception. The Stereo Cube tests for ... arc and is ideal for optometric examinations as ...
... "natural" Stereotest consists of three test plates(6mm, 3mm, ... in a range of 600 - 15 seconds. ... can only be detected if stereopsis is present. ... risk of the patient learning the correct answer. ...
Medicine Products: